


substituted by 1-15 R^{39} , halogen, $-\text{CN}$, $-\text{C}(=\text{O})\text{OR}^{30}$, $-\text{NR}^{32}\text{R}^{33}$, $-\text{OR}^{30}$, $=\text{O}$, $-\text{S}(=\text{O})_n\text{R}^{30}$, where n is 0, 1, or 2.

65. A compound as defined in any of claims 1- 56-58 or 63-64 wherein G is a group of



formula ; and R^7 is C_{3-11} cycloalkyl optionally substituted by 1-21 R^{19} and R^8 and R^9 are H.

66. A pharmaceutical composition comprising a compound of Formula (I) according to any of claims 1-65 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

67. Use of a compound of Formula (I) according to any of claims 1-65 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

68. The use according to claim 67 wherein the cancer is selected from squamous cell carcinoma, leukaemia, prostate cancer, non-Hodgkin's lymphoma, endometrial cancer, lung cancer and breast cancer.